SAGE THERAPEUTICS, INC. Environmental Analytics
Environmental and financial analysis dashboard for SAGE THERAPEUTICS, INC.. Industry: MANUFACTURING
Company Overview for SAGE THERAPEUTICS, INC.
Highlights
Showing data for FY2022
Operational Environmental Cost
$0.09m
Operational Environmental Cost Intensity
1.11%
Total Environmental Cost
N/A
Total Environmental Cost Intensity
N/A
ΔOperational Environmental Cost (2020-2022)
$-4.60m
Decoupling Rate (2020-2022)
-62%
Adjusted EBITDA
$-546m
Adjusted EBITDA Margin
-7,103%
Environmental cost statement
Showing data for FY2022
| USD MM | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| OPERATIONAL SOCIAL COST OF CARBON | ||||
| -99.25% | 20.87% | N/A | ||
| 0.13% | 0.18% | 0.17% | N/A | |
| -99.01% | 124.53% | N/A | ||
| 0.29% | 0.51% | 0.93% | N/A | |
| $5m | $0m | $0m | N/A | |
| -99.08% | 97.88% | N/A | ||
| 0.42% | 0.68% | 1.11% | N/A | |
| INDIRECT SOCIAL COST OF CARBON | ||||
| N/A | N/A | N/A | ||
| N/A | N/A | N/A | N/A | |
| N/A | N/A | N/A | ||
| N/A | N/A | N/A | N/A | |
All figures are denominated in millions of USD. USD is the base currency used to monetize, other currency equivalents are calculated using end of year exchange rates. Scope 2: Social Cost of Carbon is calculated using market-based emissions data. | ||||
Environmental cost bridge
Showing data for FY2022
Integrated financial analysis
Highlights
Showing data for FY2022
Adjusted EBITDA Margin
-7,103%
Adjusted EBIT Margin
-7,118%
EV / Adjusted EBITDA
Company Value: Placeholder
Industry Average: Placeholder
Coming soon
EV / Adjusted EBIT
Company Value: Placeholder
Industry Average: Placeholder
Coming soon
Integrated income statement
Showing data for FY2022
| USD MM | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| INCOME STATEMENT | ||||
$1,114m | $6m | $8m | $86m | |
| -99.43% | 21.87% | 1024.32% | ||
$488m | $463m | $554m | $632m | |
| 43.76% | 7340.44% | 7202.09% | 730.47% | |
$627m | $-457m | $-546m | $-545m | |
| 56.24% | -7240.44% | -7102.09% | -630.47% | |
$624m | $-461m | $-547m | $-546m | |
| 56.00% | -7306.74% | -7116.69% | -632.08% | |
| ENVIRONMENTAL COST DATA | ||||
$5m | $0m | $0m | N/A | |
| 0.42% | 0.68% | 1.11% | 0.00% | |
| FINANCIAL DATA ADJUSTED FOR OPERATIONAL ENVIRONMENTAL COST | ||||
$622m | $-457m | $-546m | N/A | |
| 55.82% | -7241.12% | -7103.20% | 0.00% | |
$619m | $-461m | $-547m | N/A | |
| 55.58% | -7307.42% | -7117.80% | 0.00% | |
All figures are denominated in millions of USD. USD is the base currency used to monetize, other currency equivalents are calculated using end of year exchange rates. | ||||
Environmental EBITDA bridge
Showing data for FY2022
Industry benchmark
MANUFACTURE OF PHARMACEUTICAL PREPARATIONS
Scope 1 (% of Sales)
0.17%
Scope 2 (% of Sales)
0.93%
Operational Environmental Cost Intensity
1.11%
Scope 3 (% of Sales)
N/A
Total Environmental Cost Intensity
N/A
Selected peer group
Showing data for FY2022
NAME | COUNTRY | OPERATIONAL ENV. COST | OPERATIONAL ENV. COST INTENSITY |
|---|---|---|---|
SAGE THERAPEUTICS, INC. | US | $0m | 1.11% |
Loading similar companies data...
Industry distribution
Showing data for FY2022
Note: Outliers are calculated using the 1.5 * IQR method, where values outside Q1 - 1.5 * IQR and Q3 + 1.5 * IQR are considered outliers.
Estimated Social Cost of Carbon Scope 3 breakdown
Percentage breakdown of Social Cost of Carbon Scope 3 into various categories
Showing data for FY2022
SCOPE 3 CATEGORY | Company (USD) | Company % | Industry Avg (USD) | Industry Avg % |
|---|---|---|---|---|
Purchased goods (1 & 2) | N/A | N/A | N/A | N/A |
Energy-related activities (3) | N/A | N/A | N/A | N/A |
Upstream transportation (4) | N/A | N/A | N/A | N/A |
Waste (5) | N/A | N/A | N/A | N/A |
Business travel (6) | N/A | N/A | N/A | N/A |
Commuting (7) | N/A | N/A | N/A | N/A |
Upstream leased assets (8) | N/A | N/A | N/A | N/A |
Downstream transportation (9) | N/A | N/A | N/A | N/A |
Processing of products (10) | N/A | N/A | N/A | N/A |
Use of products (11) | N/A | N/A | N/A | N/A |
Final treatment of products (12) | N/A | N/A | N/A | N/A |
Downstream leased assets (13) | N/A | N/A | N/A | N/A |
Franchises (14) | N/A | N/A | N/A | N/A |
Investments (15) | N/A | N/A | N/A | N/A |
Total | $0m | 100.00% | $0m | 100.00% |
Scope 3 breakdown visualization
Showing data for FY2022